1. Signaling Pathways
  2. Metabolic Enzyme/Protease
  3. Glutaminase

Glutaminase

Glutaminase is the initial enzyme in glutamine metabolism, which catalyzes the hydrolysis of glutamine to glutamate in cells. Glutaminase plays a key role in cancer cell metabolism, growth, and proliferation. In mammalian cells, there are two paralogous GLS genes, GLS1 (or GLS) and GLS2. GLS1 encodes two alternatively spliced isozymes: kidney glutaminase (KGA) and glutaminase C (GAC). GLS2 also encodes two isozymes: liver glutaminase (LGA) and glutaminase B.

GLS1 is ubiquitously expressed in various tissues, and its expression can be induced by the oncogene MYC. GLS1 is frequently activated and/or overexpressed in various types of cancer, including hepatocellular carcinoma (HCC). GLS1 has been reported to promote tumorigenesis in different types of cancer, including HCC, which is mainly attributable to its glutaminase activity and role in promoting glutamine metabolism. GLS has emerged as a critical enzyme in a number of cancer types. Elevated GLS2 enzymatic activity has also been correlated with tumor cell growth in vitro and in vivo. N-Myc activates GLS2 to promote conversion of glutamine to glutamate in MYCN-amplified neuroblastoma cells. Abrogation of GLS2 function profoundly inhibits glutaminolysis and dramatically decreases cell proliferation and survival in vitro and in vivo. However, there is controversy over the role of GLS2 as a tumor suppressor. Enzymatic activity independent of GLS2 is up-regulated via p53 or p63 and plays a role of tumor suppressor.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-146658
    Glutaminase-IN-4
    Inhibitor
    Glutaminase-IN-4 (compound 2a) is a glutaminase (GLS) inhibitor with an IC50 of 2.3 μM.
    Glutaminase-IN-4
  • HY-100446
    NTU281
    Inhibitor
    NTU281 is a potent transglutaminase-2 inhibitor. NTU281 can reduce the increases in serum creatinine and albuminuria in diabetic rats. NTU281 can also reduce glomerular collagen I accumulation, Hic-5 and α-SMA expression, and apoptosis. NTU281 can be used for researching glomerulosclerosis caused by diabetes.
    NTU281
  • HY-158378
    Trivalent hydroxyarsinothricn
    Inhibitor
    Trivalent hydroxyarsinothricn (R-AST-OH) is a covalent and irreversible kidney-type glutaminase (KGA) inhibitor. Trivalent hydroxyarsinothricn binds to the glutamine binding site and forms a covalent bond with an active site cysteine residue. Trivalent hydroxyarsinothricn selectively kills triple-negative breast cancer (TNBC) cells and is not cytotoxic to the control cell line. KGA is the enzyme that controls glutamine metabolism and is correlated with tumor malignancy.
    Trivalent hydroxyarsinothricn
  • HY-157975
    LM11
    Inhibitor
    LM11 is an inhibitor of transglutaminase 2 (TG2) with an activity of killing glioblastoma cells by maintaining TG2 in a cytotoxic conformational state.
    LM11
  • HY-162141
    MD102
    Inhibitor
    MD102 is a potent TG2 inhibitor with an IC50 value of 0.35 μM. MD102 stabilizes p53 by inhibiting TG2, inducing a decrease in p-AKT and p-mTOR downstream signaling, leading to tumor cell apoptosis.
    MD102
  • HY-146617
    GLS1 Inhibitor-4
    Inhibitor
    GLS1 Inhibitor-4 (compound 41e) is a potent GLS1 inhibitor with an IC50 of 11.86 nM. GLS1 Inhibitor-4 shows antiproliferative activity, good metabolic stability, robust GLS1 binding affinity. GLS1 Inhibitor-4 blocks the glutamine metabolism and induce the production of ROS. GLS1 Inhibitor-4 induces apoptosis and shows antitumor activity.
    GLS1 Inhibitor-4
  • HY-159962
    TGase2-IN-1
    Inhibitor
    TGase2-IN-1 (Compound 22) is an orally active inhibitor for TGase2 with an IC50 of 1.12 μM. TGase2-IN-1 inhibits TGase2 in human retinal microvascular endothelial cells with an IC50 of 0.07 μM. TGase2-IN-1 exhibits 74.6% oral bioavailability. TGase2-IN-1 inhibits retinal vascular leakage in mouse Streptozotocin (HY-13753)-induced diabetic model.
    TGase2-IN-1
  • HY-152207
    LWG-301
    Inhibitor
    LWG-301 is an allosteric inhibitor of Glutaminase 1 (GLS1) with an IC50 value of 7 nM. LWG-301 significantly block glutamine metabolism, increases intracellular ROS, thus induces apoptosis. LWG-301 exhibits moderate antitumor effects in HCT116 xenograft model.
    LWG-301
  • HY-157254
    AA10
    Inhibitor
    AA10 is a potent and irreversible transglutaminase 2 (TG2) inhibitor for cancer research.
    AA10
  • HY-W266188
    Decanoic acid-13C
    Decanoic acid-13C is the 13C-labeled Decanoic acid (HY-W015309). Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy.
    Decanoic acid-<sup>13</sup>C
  • HY-149602
    Glutaminase C-IN-2
    Inhibitor
    Glutaminase C-IN-2 (compound 11) is glutaminase C (GAC) allosteric inhibitor with an IC50 of 10.64 nM. Glutaminase C-IN-2 regulates the cellular metabolite, thereby increasing reactive oxygen species (ROS) by blocking glutamine metabolism. Glutaminase C-IN-2 has anticancer effects.
    Glutaminase C-IN-2
  • HY-148241
    A-446
    Inhibitor
    A-446 is a potent glutaminase (GLS) inhibitor with an IC50 value of 31 nM.
    A-446
  • HY-155643
    PROTAC TG2 degrader-1
    Inhibitor
    PROTAC TG2 degrader-1 (compound 11) is a von Hippel-Lindau (VHL)-based PROTAC targeting tissue transglutaminase (TG2) with a KD of 68.9 μM. PROTAC TG2 degrader-1 reduces TG2 in ovarian cancer cells in a proteasome-dependent manner.
    PROTAC TG2 degrader-1
  • HY-N2916
    Barbinervic acid
    Inhibitor
    Barbinervic acid is a glutaminase inhibitor with an IC50 of 14 μM. Barbinervic acid can be used for the study of neurodegenerative diseases.
    Barbinervic acid
  • HY-W020050S
    Cystamine-d8 dihydrochloride
    Cystamine-d8 (dihydrochloride) is the deuterium labeled Cystamine (dihydrochloride). Cystamine (dihydrochloride) is the disulfide form of the free thiol, cysteamine. Cystamine is an orally active transglutaminase (Tgase) inhibitor. Cystamine also has inhibition activity for caspase-3 with an IC50 value of 23.6 μM. Cystamine can be used for the research of severals diseases including Huntington's disease (HD).
    Cystamine-d<sub>8</sub> dihydrochloride
  • HY-12683R
    BPTES (Standard)
    Inhibitor
    BPTES (Standard) is the analytical standard of BPTES. This product is intended for research and analytical applications. BPTES is an allosteric and selective glutaminase inhibitor with an IC50 of 0.16 μM.
    BPTES (Standard)
  • HY-W015309R
    Decanoic acid (Standard)
    Inhibitor
    Decanoic acid (Standard) is the analytical standard of Decanoic acid. This product is intended for research and analytical applications. Decanoic acid is a key component of the medium-chain triglyceride (MCT) found in coconut oil. Decanoic acid is a brain-penetrant and non-competitive inhibitor of AMPA receptor showing antiseizure activity in rats. Decanoic acid reduces tyrosinase activity and inhibits melanosome maturation. Decanoic acid suppresses the phosphorylation of c-Met and induced apoptosis in hepatocellular carcinoma (HCC) cells by inhibiting the expression of various oncogenic proteins, which is promising for research in the field of mTORC1 signaling, HCC and epilepsy.
    Decanoic acid (Standard)
  • HY-12248R
    Telaglenastat (Standard)
    Inhibitor
    Telaglenastat (Standard) is the analytical standard of Telaglenastat. This product is intended for research and analytical applications. Telaglenastat (CB-839) is a first-in-class, selective, reversible and orally active glutaminase 1 (GLS1) inhibitor. Telaglenastat selectively inhibits GLS1 splice variants KGA (kidney-type glutaminase) and GAC (glutaminase C) compared to GLS2. The IC50s are 23 nM and 28 nM for endogenous glutaminase in mouse kidney and brain, respectively. Telaglenastat inuduces autophagy and has antitumor activity.
    Telaglenastat (Standard)
  • HY-165426
    HB-230
    HB-230 is a red fluorescent transglutaminase 2 (TG2) probe. HB-230 complexes with TG2 and α2-macroglobulin via the LRP1 pathway for efficient endocytosis. The excitation and emission wavelengths of HB-230 are 649 and 665 nm, respectively.
    HB-230
  • HY-114929
    THDP17
    Inhibitor
    THDP17 is an orally active glutaminase inhibitor. THDP17 decreases ammonia production through glutaminase inhibition.
    THDP17
Cat. No. Product Name / Synonyms Application Reactivity